Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The role of opioids in cancer pain.

Literature DB >> 16210282

The role of opioids in cancer pain.

Columba Quigley¹.

Abstract

Entities: Disease

Mesh：

Substances：
Analgesics, Opioid

Year: 2005 PMID： 16210282 PMCID： PMC1246085 DOI： 10.1136/bmj.331.7520.825

Source DB: PubMed Journal: BMJ ISSN： 0959-8138

× No keyword cloud information.

28 in total

1. Pain treatment and outcomes for patients with advanced cancer who receive follow-up care at home.

Authors: S Mercadante
Journal: Cancer Date: 1999-04-15 Impact factor: 6.860

2. Opioid pharmacotherapy in the management of cancer pain: a survey of strategies used by pain physicians for the selection of analgesic drugs and routes of administration.

Authors: N J Cherny; V Chang; G Frager; J M Ingham; P J Tiseo; B Popp; R K Portenoy; K M Foley
Journal: Cancer Date: 1995-10-01 Impact factor: 6.860

Review 3. Peak plasma concentrations after oral morphine: a systematic review.

Authors: S L Collins; C C Faura; R A Moore; H J McQuay
Journal: J Pain Symptom Manage Date: 1998-12 Impact factor: 3.612

4. Comparison of the analgesic and intestinal effects of fentanyl and morphine in rats.

Authors: A A Megens; K Artois; J Vermeire; T Meert; F H Awouters
Journal: J Pain Symptom Manage Date: 1998-04 Impact factor: 3.612

5. Long-term treatment of cancer pain with transdermal fentanyl.

Authors: B Donner; M Zenz; M Strumpf; M Raber
Journal: J Pain Symptom Manage Date: 1998-03 Impact factor: 3.612

6. Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group.

Authors: S Ahmedzai; D Brooks
Journal: J Pain Symptom Manage Date: 1997-05 Impact factor: 3.612

7. Transdermal buprenorphine in the treatment of chronic pain: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study.

Authors: Jürgen Sorge; Reinhard Sittl
Journal: Clin Ther Date: 2004-11 Impact factor: 3.393

8. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study.

Authors: R K Portenoy; R Payne; P Coluzzi; J W Raschko; A Lyss; M A Busch; V Frigerio; J Ingham; D B Loseth; E Nordbrock; M Rhiner
Journal: Pain Date: 1999-02 Impact factor: 6.961

9. Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain.

Authors: E Bruera; M Belzile; E Pituskin; R Fainsinger; A Darke; Z Harsanyi; N Babul; I Ford
Journal: J Clin Oncol Date: 1998-10 Impact factor: 44.544

10. Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study.

Authors: Detlev F J Zech; Stefan Grond; John Lynch; Dagmar Hertel; Klaus A Lehmann
Journal: Pain Date: 1995-10 Impact factor: 6.961

13 in total

1. Treatment of cancer pain: Spanish Society of Medical Oncology (SEOM) recommendations for clinical practice.

Authors: Juan A Virizuela; Yolanda Escobar; Javier Cassinello; Pablo Borrega
Journal: Clin Transl Oncol Date: 2012-07 Impact factor: 3.405

2. Treatment of pain in children after limb-sparing surgery: an institution's 26-year experience.

Authors: Doralina L Anghelescu; Linda L Oakes; Gisele M Hankins
Journal: Pain Manag Nurs Date: 2010-09-20 Impact factor: 1.929

Review 3. Methylnaltrexone.

Authors: Karly P Garnock-Jones; Kate McKeage
Journal: Drugs Date: 2010-05-07 Impact factor: 9.546

Review 4. Opioid induced bowel disease: a twenty-first century physicians' dilemma. Considering pathophysiology and treatment strategies.

Authors: Ankush Sharma; M Mazen Jamal
Journal: Curr Gastroenterol Rep Date: 2013-07